Global Orphan Drug Market Drive by High Profitability Rate

Release Date: 07-Aug-2014

Global Orphan Drug Market Report Highlights:

• Orphan Designated Drugs in Clinical Phase: 600
• Marketed Orphan Designated Drugs: 281
• Highest Number of Drugs in Phase-2 Trial: 231
• US Dominates Clinical Trial Process: 350 in Pipeline (Research till Registration)
• Indication for Clinical Trials for Orphan Drug: More than 30% for Cancer Treatment
• Share of Biological in Orphan Drug: More than 60%
• Major Market: US (Sales > US$ 40 Billion)
•  Why Shift to Orphan Drugs
• Global & Regional Orphan Drug Market Overview
• Orphan Drug Designation Criteria Across US, Europe & Asia
• Market Specific Reimbursement Policy for US, Europe & Asia
• Regulatory Framework for US, Europe & Asia
• Orphan Drug Pipeline by Phase, Orphan Designated Indication & Country

Though the developmental costs are very high, the potential to earn significant profits certainly outweigh such high costs. As an illustration, in 2010, Soliris, which is used to treat paroxysymal nocturnal hemoglobinuria, a rare life-threatening blood disease was the most expensive drug in the USA in 2012 costing more than $440,000 annually. The developer of this drug, Alexion Pharmaceuticals, earned a total revenue of USD 1.134 billion in sales. Given that the target population is only 4,000 to 6,000 people, the revenue earned by Soliris shows the immense potential that this industry holds for the future.

Additionally, the repositioning of orphan drugs as treatment to other rare diseases can increase the sales volumes. It has been observed that close to 15 percent of the drugs had subsequent launches for other rare illnesses. Also, it was observed that among the top 10 orphan drugs, six had more than one rare disease indication with a peak value averaging USD 34.3 billion in overall sales potential, compared with USD 8.1 billion for drugs with only one such indication.

For Report Sample Visit: Global Orphan Drug Market Outlook 2018

Or Contact: avinash@kuickresearch.com